Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc Cabel

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2017
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal CarcinomatosisHugo Gortais, Catherine Daniel, François-Clément Bidard, et al.
NPJ Breast Cancer|November 29, 2024
Circulating tumor cells in breast cancer: clinical validity and utilityThibault Thomas-Bonafos, Jean Yves Pierga, François-Clément Bidard, et al.
Cancers|August 7, 2021
Present and Future Research on Anal Squamous Cell CarcinomaLaurie Spehner, Jihane Boustani, Luc Cabel, et al.
NPJ Breast Cancer|June 29, 2018
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancerMarie-Laure Tanguy, Luc Cabel, Fréderique Berger, et al.
JNCI Cancer Spectrum|July 31, 2019
Circulating Tumor Cells in Early Breast CancerLaura Thery, Alessandra Meddis, Luc Cabel, et al.
International Journal of Clinical Oncology|February 27, 2017
Circulating tumor cells: clinical validity and utilityLuc Cabel, Charlotte Proudhon, Hugo Gortais, et al.
Expert Review of Molecular Diagnostics|June 13, 2019
ESR1 mutations: a new biomarker in breast cancerMarcela Carausu, François-Clément Bidard, Celine Callens, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapyClarice S Groeneveld, Jacqueline Fontugne, Luc Cabel, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literatureMarcela Carausu, Arnaud Beddok, Adriana Langer, et al.
American Journal of Clinical Oncology|August 8, 2025
Real-world Safety of Concurrent Pembrolizumab and Radiotherapy in Triple-negative Breast CancerAssile El Fakih, Pierre Loap, Luc Cabel, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2017
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal CarcinomatosisHugo Gortais, Catherine Daniel, François-Clément Bidard, et al.
NPJ Breast Cancer|November 29, 2024
Circulating tumor cells in breast cancer: clinical validity and utilityThibault Thomas-Bonafos, Jean Yves Pierga, François-Clément Bidard, et al.
Cancers|August 7, 2021
Present and Future Research on Anal Squamous Cell CarcinomaLaurie Spehner, Jihane Boustani, Luc Cabel, et al.
NPJ Breast Cancer|June 29, 2018
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancerMarie-Laure Tanguy, Luc Cabel, Fréderique Berger, et al.
JNCI Cancer Spectrum|July 31, 2019
Circulating Tumor Cells in Early Breast CancerLaura Thery, Alessandra Meddis, Luc Cabel, et al.
International Journal of Clinical Oncology|February 27, 2017
Circulating tumor cells: clinical validity and utilityLuc Cabel, Charlotte Proudhon, Hugo Gortais, et al.
Expert Review of Molecular Diagnostics|June 13, 2019
ESR1 mutations: a new biomarker in breast cancerMarcela Carausu, François-Clément Bidard, Celine Callens, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapyClarice S Groeneveld, Jacqueline Fontugne, Luc Cabel, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literatureMarcela Carausu, Arnaud Beddok, Adriana Langer, et al.
American Journal of Clinical Oncology|August 8, 2025
Real-world Safety of Concurrent Pembrolizumab and Radiotherapy in Triple-negative Breast CancerAssile El Fakih, Pierre Loap, Luc Cabel, et al.
Pageof 8